

# Resource Summary Report

Generated by [RRID](#) on Aug 2, 2026

## FGF Receptor 3 (C51F2)

RRID:AB\_2246903

Type: Antibody

---

### Proper Citation

Cell Signaling Technology Cat# 4574, RRID:AB\_2246903

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2246903](http://antibodyregistry.org/AB_2246903)

**Proper Citation:** Cell Signaling Technology Cat# 4574, RRID:AB\_2246903

**Target Antigen:** FGFR3

**Host Organism:** rabbit

**Clonality:** monoclonal

**Comments:** Applications: W, IP, IHC-P, IF-IC. Consolidation on 11/2018: AB\_10287934, AB\_2246903, AB\_2721171.

**Antibody Name:** FGF Receptor 3 (C51F2)

**Description:** This monoclonal targets FGFR3

**Target Organism:** human

**Clone ID:** C51F2

**Antibody ID:** AB\_2246903

**Vendor:** Cell Signaling Technology

**Catalog Number:** 4574

**Record Creation Time:** 20250820T055130+0000

**Record Last Update:** 20250820T223829+0000

---

### Ratings and Alerts

No rating or validation information has been found for FGF Receptor 3 (C51F2).

No alerts have been found for FGF Receptor 3 (C51F2).

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 11 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. NPJ breast cancer, 11(1), 135.

Chamessian A, et al. (2025) Expression of Fibroblast Growth Factor Receptor 3 (FGFR3) in the Human Peripheral Nervous System: Implications for the Putative Pathogenic Role of FGFR3 Autoantibodies in Neuropathy. bioRxiv : the preprint server for biology.

Yang Y, et al. (2024) A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants. Cancer research, 84(13), 2169.

Ye T, et al. (2024) Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma. Cell reports, 43(5), 114211.

Ma L, et al. (2023) Discovery of a Selective and Orally Bioavailable FGFR2 Degradar for Treating Gastric Cancer. Journal of medicinal chemistry, 66(11), 7438.

Gou X, et al. (2023) Kinome reprogramming is a targetable vulnerability in ESR1 fusion-driven breast cancer. Cancer research.

Di Persio S, et al. (2021) Single-cell RNA-seq unravels alterations of the human spermatogonial stem cell compartment in patients with impaired spermatogenesis. Cell reports. Medicine, 2(9), 100395.

Vigneswaran K, et al. (2021) YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(5), 1553.

Day EK, et al. (2020) Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling. Cell reports, 30(10), 3383.

Oberlick EM, et al. (2019) Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. Cell reports, 28(9), 2331.

Zhang W, et al. (2018) Adaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth. Cell reports, 24(5), 1266.